Everest Organics Peer Comparison

BSE: 524790

₹239.90

₹4.40 (1.87%)

As on 04-Nov-2026 15:50IST

Market cap

₹243 Cr

Revenue (TTM)

₹191 Cr

P/E Ratio

46.2

P/B Ratio

Div. Yield

0 %

Edit

	Everest Organics	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
Market cap (₹ Cr)	243	17,879	18,346	17,662	16,649
Revenue (₹ Cr)	191	1,682	2,287	2,570	3,330
Net Profit (₹ Cr)	5.26	273.51	678.07	735.15	720.77
Net Margin (%)	2.74	16.19	28.10	26.88	21.60
RoE (%)	7.10	11.15	19.73	19.16	18.93
Price to Earnings	46.20	60.13	27.57	20.55	23.53
Price-To-Book	3.01	6.66	5.00	4.01	4.02

Income Statement (₹ Cr)

	Everest Organics	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
Operating Revenue	190.78	1,682.47	2,287.33	2,569.77	3,329.63
Total Income	191.89	1,689.83	2,413.29	2,735.39	3,337.47
Total Expenditure	171.07	1,203.91	1,490.75	1,628.14	2,168.88
EBITDA	19.70	478.55	796.58	941.63	1,160.75
Depreciation	6.56	126.01	78.10	57.58	285.40
EBIT	13.15	352.55	718.48	884.05	875.35
Interest	6.85	52.11	0.88	7.69	187.51
Other Income	1.12	7.37	125.96	165.62	7.84
Exceptional Items	0.00	12.16	0.00	-49.16	-53.14
Profit before Tax	7.41	319.96	843.56	992.82	642.54
Provision for Tax	2.16	46.45	165.49	257.67	-78.23
Profit after Tax	5.26	273.51	678.07	735.15	720.77

	Everest Organics	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
Shareholder's Funds	75.48	2,591.20	3,586.42	4,202.90	4,144.34
Minority Interest	0.00	0.00	-12.71	0.00	-10.85
Non-Current Liabilities	12.13	266.35	28.74	91.50	758.48
Current Liabilities	152.20	848.06	385.94	627.48	2,681.14
Total Liabilities	239.80	3,705.61	4,037.51	4,921.88	7,246.72

	Everest Organics	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
Non-Current Assets	68.38	2,525.44	1,291.22	770.28	5,578.78
Current Assets	167.43	1,109.77	2,585.66	3,803.22	1,800.86
Total Assets	239.80	3,705.61	4,037.51	4,921.88	7,246.72
Total Debt*	49.93	657.97	0.57	2.50	2,309.68
Net Current Assets	15.23	261.71	2,199.72	3,175.74	-880.28
Contingent Liabilities	4.45	160.01	17.53	370.49	51.57

	Everest Organics	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
Cash From Operating Activities	4.17	342.18	523.24	967.57	537.99
Cash Flow from Investing Activities	-1.72	-325.92	-582.30	-561.67	-369.46
Cash from Financing Activities	-8.45	13.62	-46.46	-798.31	-313.53
Net Cash Inflow / Outflow	-5.99	29.88	-105.52	-392.41	-145.00

	Everest Organics	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
ROCE (%)	11.98	11.43	24.97	23.39	14.47
ROE (%)	7.10	11.15	19.73	19.16	18.93
ROA (%)	2.26	7.80	18.69	14.95	9.78
EBIT Margin (%)	6.89	20.95	31.41	34.40	26.29
Net Margin (%)	2.74	16.19	28.10	26.88	21.60
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Everest Organics	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
Revenue Growth (%)	5.49	27.91	15.01	10.69	11.06
EBIT Growth (%)	41.22	58.32	18.45	24.14	13.71
Net Profit Growth (%)	-15.23	149.56	19.61	-9.09	60.98
EPS Growth (%)	-20.40	-3.57	17.73	14.40	80.38
Book Value Growth (%)	9.47	9.67	26.75	-0.34	36.71

	Everest Organics	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
Price / Earnings	43.52	64.95	26.98	22.52	21.38
Price / Book Value	2.91	6.78	4.89	3.94	3.94
Dividend Yield (%)	0.00	0.06	0.34	1.98	0.00
EV/EBITDA	14.42	39.32	21.28	15.15	16.00
Market Cap (₹ Cr)	197.55	6,819.66	11,439.22	21,592.90	17,980.08

	Everest Organics	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
Debt to Equity	0.10	0.07	0.00	0.00	0.10
Short term debt to equity ratio	0.51	0.16	0.00	0.00	0.12
Current Ratio	1.10	1.31	6.70	6.06	0.67
Quick Ratio	0.81	0.88	5.59	5.31	0.49
Interest Coverage	2.08	7.14	959.59	130.11	4.43

	Everest Organics	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
Debtors to sales (%)	60.89	30.84	36.10	7.07	18.98
Asset Turnover	0.82	0.48	0.63	0.52	0.45
Receivable days	165.70	113.81	121.68	26.06	63.88
Inventory Days	72.94	84.76	63.83	65.95	43.27
Payable days	259.13	101.94	108.28	81.01	151.85
Cash Conversion Cycle	-20.50	96.62	77.23	11.00	-44.70

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.